WO2018236185A3 - Médicament contre la septicémie et procédé de criblage associé - Google Patents

Médicament contre la septicémie et procédé de criblage associé Download PDF

Info

Publication number
WO2018236185A3
WO2018236185A3 PCT/KR2018/007102 KR2018007102W WO2018236185A3 WO 2018236185 A3 WO2018236185 A3 WO 2018236185A3 KR 2018007102 W KR2018007102 W KR 2018007102W WO 2018236185 A3 WO2018236185 A3 WO 2018236185A3
Authority
WO
WIPO (PCT)
Prior art keywords
screening method
sepsis
method therefor
medicine
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2018/007102
Other languages
English (en)
Korean (ko)
Other versions
WO2018236185A2 (fr
Inventor
이승엽
이동권
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sungkyunkwan University
Original Assignee
Sungkyunkwan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sungkyunkwan University filed Critical Sungkyunkwan University
Publication of WO2018236185A2 publication Critical patent/WO2018236185A2/fr
Publication of WO2018236185A3 publication Critical patent/WO2018236185A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une composition pharmaceutique pour la prévention ou le traitement de la septicémie, la composition contenant un inhibiteur de l'opéron VncRs ou un inhibiteur de l'activité de la lactoferrine chez Diplococcus pneumoniae, et un procédé de criblage à la recherche d'un agent préventif ou thérapeutique contre la septicémie.
PCT/KR2018/007102 2017-06-22 2018-06-22 Médicament contre la septicémie et procédé de criblage associé Ceased WO2018236185A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170079336A KR102114739B1 (ko) 2017-06-22 2017-06-22 패혈증 치료제 및 이의 스크리닝 방법
KR10-2017-0079336 2017-06-22

Publications (2)

Publication Number Publication Date
WO2018236185A2 WO2018236185A2 (fr) 2018-12-27
WO2018236185A3 true WO2018236185A3 (fr) 2019-04-11

Family

ID=64735824

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/007102 Ceased WO2018236185A2 (fr) 2017-06-22 2018-06-22 Médicament contre la septicémie et procédé de criblage associé

Country Status (2)

Country Link
KR (1) KR102114739B1 (fr)
WO (1) WO2018236185A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113577102B (zh) * 2021-08-09 2022-09-16 西北大学 铁纳米簇用于制备抗败血症及其诱发的心肌损伤药物的应用
KR20250176627A (ko) 2024-06-12 2025-12-22 사회복지법인 삼성생명공익재단 miR-223 억제제를 포함하는 패혈증 예방 또는 치료용 약학적 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120010906A (ko) * 2010-07-27 2012-02-06 성균관대학교산학협력단 ｐｅｐ27 유전자 돌연변이를 포함하는 약독화된 폐렴구균 균주 및 이의 용도
CN103965354A (zh) * 2014-05-23 2014-08-06 苏州大学 乳铁蛋白单克隆抗体及其应用以及相关产品

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120010906A (ko) * 2010-07-27 2012-02-06 성균관대학교산학협력단 ｐｅｐ27 유전자 돌연변이를 포함하는 약독화된 폐렴구균 균주 및 이의 용도
CN103965354A (zh) * 2014-05-23 2014-08-06 苏州大学 乳铁蛋白单克隆抗体及其应用以及相关产品

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HAAS, WOLFGANG ET AL.: "Revising the Role of the Pneumococcal Vex-vncRS Locus in Vancomycin Tolerance", J OURNAL OF BACTERIOLOGY, vol. 186, no. 24, 2004, pages 8463 - 8471, XP055590123 *
LEE, DONG KWON, A STUDY ON STREPTOCOCCUS PNEUMONIAE SEPSIS-VANCOMYCIN RESISTANT BACILLUS, 2015 *
SUNG, WOO SANG ET AL.: "Mode of Antibacterial Action of a Signal Peptide, Pep 27 from Streptococcus Pneumoniae", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 363, 2007, pages 806 - 810, XP022288934, DOI: doi:10.1016/j.bbrc.2007.09.041 *

Also Published As

Publication number Publication date
KR102114739B1 (ko) 2020-05-25
KR20190000241A (ko) 2019-01-02
WO2018236185A2 (fr) 2018-12-27

Similar Documents

Publication Publication Date Title
EP3699174A4 (fr) Composition pour la prévention ou le traitement de maladies liées au tnf, contenant un nouveau dérivé en tant que principe actif, et procédé d'inhibition de l'activité du tnf à l'aide de celle-ci
BR112018072542A2 (pt) derivados de piridiniltriazol substituído com amida e usos dos mesmos
MX2022016463A (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
EP3498279A4 (fr) Composition pharmaceutique comprenant comme principes actifs de l'amodiaquine et un médicament anti-diabète, destinée à la prévention ou le traitement du diabète
MA40814A1 (fr) Compositions pharmaceutiques pour thérapie combinée
FR2949044B1 (fr) Composition comprenant une fraction d'insaponifiable
PH12020500205A1 (en) Anti-cd147 antibody
MA43918A (fr) Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31
EP2137175A4 (fr) Nouveau composé à base de phénanthrènequinone et composition pharmaceutique contenant ce dernier utilisé pour le traitement ou la prévention du syndrome métabolique impliquant des maladies
EP3489252A4 (fr) Peptide ayant une activité anticancéreuse, composition pharmaceutique pour le traitement et la prévention du cancer, composition alimentaire de santé fonctionnelle et composition cosmétique fonctionnelle le contenant en tant que principe actif
MY201921A (en) Agent for preventing or treating fat-associated diseases and/or inflammation
MA50406B1 (fr) Inhibiteurs pyrazole de magl
ZA202302155B (en) Interferon-based cancer treatment method and pharmaceutical composition
EP3539951A4 (fr) Nouveau composé de pyrimidine, son procédé de préparation et composition pharmaceutique le contenant en tant que principe actif pour la prévention ou le traitement du cancer et des maladies inflammatoires
EP4008718C0 (fr) Dérivé d'hétéroarylamidopyridinol et composition pharmaceutique le comprenant en tant que principe actif pour prévenir ou traiter une maladie auto-immune
EP3728567A4 (fr) Procédés pour le développement de produits pharmaceutiques pour le traitement d'affections neurodégénératives
PH12020550532A1 (en) Agent for preventing or treating small intestinal injury induced by non-steroidal anti-inflammatory drug and proton pump inhibitor
MX2014000204A (es) Metodo de administracion y tratamiento.
EP3336100A4 (fr) Peptide ayant pour effet de prévenir ou traiter des maladies du système nerveux central et composition pharmaceutique pour la prévention et le traitement de maladies du système nerveux central, contenant ce dernier en tant que principe actif
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
EP3650029A4 (fr) Composition pharmaceutique pour la prévention et le traitement de la néphropathie diabétique, contenant un dérivé d'adénosine
EP3698801A4 (fr) Composition pharmaceutique pour prévenir et traiter le diabète contenant un sel de zinc, un cyclo-hispro et un antidiabétique à titre de principes actifs
Wang et al. Pleiotropic effects of atorvastatin on monocytes in atherosclerotic patients
MA42455B1 (fr) Nouveau composé hétérocyclique, procédé de préparation associé et composition pharmaceutique le comprenant
Walsh et al. Not just an antibiotic target: exploring the role of type I signal peptidase in bacterial virulence

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18821307

Country of ref document: EP

Kind code of ref document: A2